Results 131 to 140 of about 699 (156)

Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain

Journal of Comparative Effectiveness Research, 2021
Aim: Oliceridine, a new class of μ-opioid receptor agonist, is selective for G-protein signaling (analgesia) with limited recruitment of β-arrestin (associated with adverse outcomes) and may provide a cost-effective alternative versus conventional opioid morphine for postoperative pain. Patients & methods:
Kit N Simpson, Michael J Fossler, Linda Wase   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Oliceridine for the Management of Acute Postoperative Pain

Annals of Pharmacotherapy, 2021
Objective To review the pharmacological characteristics, clinical evidence, and place in the management of acute postoperative pain severe enough to require an intravenous opioid. Data Sources A comprehensive literature search was ...
Junyi Yang
exaly   +3 more sources

Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain [PDF]

Pain and Therapy, 2021
IntroductionAdvanced age and obesity are reported to increase the risk of opioid-induced respiratory depression (OIRD). Oliceridine, an intravenous opioid, is a G-protein-biased agonist at the µ-opioid receptor that may provide improved safety.
Marek Brzezinski, Gregory B Hammer, Keith A Candiotti   +2 more
exaly   +2 more sources

Oliceridine

Hospital Pharmacy, 2021
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Brittany M. Craft, Danial E. Baker
openaire   +1 more source

Oliceridine: First Approval

Drugs, 2020
Oliceridine (Olinvyk™, Trevena, Inc.) is a novel μ opioid agonist that was recently approved in the USA for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Anthony Markham, Markham Anthony
exaly   +3 more sources

Preclinical discovery and development of oliceridine (Olinvyk®) for the treatment of post-operative pain

Expert Opinion on Drug Discovery, 2022
Opioids acting at the MOP (mu:µ) receptor produce analgesia but also side effects. There is debate suggesting opioid receptors produce analgesia via G-protein and side-effects via β-arrestin-2 pathways. Opioids targeting G-proteins over the arrestins (bias) offer potential therapeutic advantages.
David G Lambert
exaly   +3 more sources

A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain

Expert Review of Neurotherapeutics, 2022
Oliceridine is a G protein-selective (biased) agonist at the μ-opioid receptor, with less recruitment of β-arrestin-2, a signaling pathway associated with opioid-related adverse events. Nonclinical evidence showed that oliceridine elicits a rapid systemic analgesic effect while attenuating opioid-related adverse events.Three pivotal studies in patients
Eugene R Viscusi
exaly   +3 more sources

Essential role of P-glycoprotein in the mechanism of action of oliceridine

Neuropsychopharmacology, 2022
Mu opioid receptor (MOR) agonists comprise the most effective analgesics, but their therapeutic utility is limited by adverse effects. One approach for limiting such effects has been to develop "biased" MOR agonists that show preference for activating G protein over β-Arrestin signaling.
Emilya Ventriglia, Arianna Rizzo, Juan L. Gomez, Jacob Friedman, Sherry Lam, Oscar Solís, Rana Rais, Jordi Bonaventura, Michael Michaelides   +8 more
openaire   +2 more sources

Over View of Oliceridine Newer Opioid Analgesic

Indian Journal of Anesthesia and Analgesia, 2022
Pain relief requires a balance between adequate analgesia and risk of adverse effects. Opioids remain the cornerstone for managing moderate to severe pain, but are associated with opioid-induced respiratory depression (OIRD) and gastrointestinal complications. Opioids exert their analgesic effects predominantly via G-protein signaling, however, adverse
Anurita Konnur, Yoganarasimha N, Kripa Anand   +2 more
openaire   +1 more source

Oliceridine for postoperative pain and opioid-related complications: The intravenous oliceridine and opioid-related complications (VOLITION) prospective cohort study

Journal of Clinical Anesthesia
Oliceridine is a G protein-selective μ-opioid receptor agonist with reduced β-arrestin activation that may produce fewer opioid-related adverse effects (ORAEs) than traditional opioids. The VOLITION prospective cohort study evaluated oliceridine for management of postoperative pain and evaluated ORAEs.We enrolled 204 patients scheduled for major ...
Daniel I Sessler, Sabry Ayad, Toby N Weingarten   +2 more
exaly   +3 more sources